Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors
Dr. Ascheim has over 30 years of clinical and executive experience advancing breakthrough therapies, including gene, cell, and biologicsJoshua HareDeborah D. Ascheim, M.D.MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. NASDAQ:LGVN a clinical stage biotechnology company developing cellular…